Intestinal subepithelial myofibroblasts in inflammatory bowel disease: fibroblast heterogeneity, fibrosis, and therapeutic targeting - Top-Institutions - MDSpire

Intestinal subepithelial myofibroblasts in inflammatory bowel disease: fibroblast heterogeneity, fibrosis, and therapeutic targeting

  • By

  • Fang Li

  • Chao Xu

  • Jun Chen

  • Teng Lei

  • Xigui Tian

  • Yuanling Zhang

  • Guoqing Chen

  • June 24, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Gastroenterology
    • GI Surgery

  • #2

    Cedars-Sinai Medical Center
    Cedars-Sinai Medical Center

    Los Angeles, California

    Key Differentiators

    • Gastroenterology

  • #3

    Osaka University School of Medicine
    Osaka University School of Medicine

    Osaka, Japan

    Key Differentiators

    • Gastroenterology

  • #4

    Hyogo Medical University
    Hyogo Medical University

    Hyogo, Japan

    Key Differentiators

    • Gastroenterology

  • #5

    STAR Consortium
    STAR Consortium

    N/A, N/A

    Key Differentiators

    • Gastroenterology

Original Source(s)

Intestinal subepithelial myofibroblasts in inflammatory bowel disease: fibroblast heterogeneity, fibrosis, and therapeutic targeting

  • by Fang Li, Chao Xu, Jun Chen, Teng Lei, Xigui Tian, Yuanling Zhang, Guoqing Chen

  • June 24, 2026

Related Content

AF6 orchestrates macrophage polarization via JAK2-STAT3 signaling and supports intestinal regeneration by stimulating stem cell proliferation

Microbiota metabolite butyrate alleviates intestinal inflammation associated with enhanced autophagy-related signaling in DSS-induced colitis

Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis